JPMorgan Sees Pharmasset (VRUS) Doubling From Here, Significantly Raises Price Target
Tweet Send to a Friend
JPMorgan doubled their price target on Overweight-rated Pharmasset (NASDAQ: VRUS) from $100 to $200 citing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
